生命科学资讯

The Bull Case For Agilent Technologies (A) Could Change Following New PD-L1 Test Approval And Dividend News - simplywall.st

Moderna vs FDA; Paul Hudson out at Sanofi; Why clinical trials are so costly; and more

Agilent Technologies, Inc. $A Shares Sold by ING Groep NV - MarketBeat

Thermo Fisher Scientific (TMO) Announces $3.8 Billion Senior Not - GuruFocus

Assetmark Inc. Boosts Position in Agilent Technologies, Inc. $A - MarketBeat

Illumina (NASDAQ:ILMN) Upgraded by Wall Street Zen to Strong-Buy Rating - MarketBeat

Risk Factors Weigh on 10X Genomics: Uncertain Guidance, Stock Volatility, and Capital-Raising Challenges - TipRanks

Decoding 10x Genomics Inc (TXG): A Strategic SWOT Insight - GuruFocus

Shrinking TTM Loss At 10x Genomics (TXG) Tests Bearish Earnings Narratives - simplywall.st

Shrinking TTM Loss At 10x Genomics (TXG) Tests Bearish Earnings Narratives - simplywall.st

'It's really a dire time for patients': Biohaven CEO says FDA red tape is blocking access to rare disease treatments

FDA rejects Disc's rare disease drug despite commissioner's voucher

From sample to insight: Streamlining analysis with the Illumina 5-base solution - Illumina

Illumina completes acquisition of SomaLogic from Standard BioTools - BizWest

Expert Outlook: 10x Genomics Through The Eyes Of 10 Analysts - Benzinga

With the FDA's Moderna decision, vaccine makers face increasingly uncertain regulatory environment

FDA clears Encora Therapeutics’ wearable wrist device for essential tremor

What were the biggest clinical trial flops of 2025?

After R&D head exits, Immunocore CEO pairs ambition with caution for growing cancer portfolio

BofA Maintains Hold Rating on Agilent Technologies (A) After Q2 Report - MSN